FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221036987> ?p ?o ?g. }

• W4221036987 endingPage "1894" @default.
• W4221036987 startingPage "1881" @default.
• W4221036987 abstract "Despite levodopa’s superior efficacy in reducing the motor symptoms of Parkinson’s disease (PD), its risk to induce motor complications requires consideration of the pros and cons of initiating treatment with levodopa-sparing strategies. The current drive toward early levodopa monotherapy is primarily driven by safety and tolerability concerns with dopamine agonists and only mild efficacy of other available approaches. Recently, P2B001, a novel once-daily combination of low-dose, extended-release formulations of pramipexole and rasagiline (0.6 mg and 0.75 mg respectively), has entered clinical development. In this drug evaluation, we review the preclinical and current clinical data for P2B001 and its components. The P2B001 combination has the potential to provide greater efficacy than either pramipexole or rasagiline alone and a better tolerability profile compared to higher dosage dopamine agonist monotherapy, while maintaining the advantage of lower motor complication risk than levodopa. Parkinson’s disease is the fastest growing neurologic disorder across the globe. Once diagnosed, it is now generally agreed that there is no clinical rationale to postpone symptomatic treatment in people who develop Parkinson’s-related disability. There are three main treatment options available for use in early Parkinson’s disease: levodopa, dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors. Of these, there is a current push toward using levodopa as the main first-line therapy. This is primarily because of the significant safety and tolerability concerns with dopamine agonists and only mild efficacy of MAO-B inhibitors. Recently, P2B001, a novel drug formulation combining once-daily, extended-release, low dosages of the dopamine agonist pramipexole and the MAO-B inhibitor rasagiline (0.6 mg and 0.75 mg respectively), has entered clinical development. In this article, the authors review the preclinical and current clinical data on P2B001 and its components. The P2B001 combination has the potential to provide greater efficacy than either pramipexole or rasagiline alone and a better tolerability profile compared to higher dosage dopamine agonist monotherapy, while maintaining the advantage of lower motor complication risk than levodopa." @default.
• W4221036987 created "2022-04-03" @default.
• W4221036987 creator A5018228116 @default.
• W4221036987 creator A5028592744 @default.
• W4221036987 creator A5039274182 @default.
• W4221036987 creator A5049671447 @default.
• W4221036987 creator A5054677591 @default.
• W4221036987 creator A5080057970 @default.
• W4221036987 creator A5081208955 @default.
• W4221036987 date "2022-03-10" @default.
• W4221036987 modified "2023-10-10" @default.
• W4221036987 title "P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease" @default.
• W4221036987 cites W1225351505 @default.
• W4221036987 cites W1479935944 @default.
• W4221036987 cites W1697892179 @default.
• W4221036987 cites W1965803528 @default.
• W4221036987 cites W1976745439 @default.
• W4221036987 cites W1985336431 @default.
• W4221036987 cites W1985460799 @default.
• W4221036987 cites W2011130816 @default.
• W4221036987 cites W2012185697 @default.
• W4221036987 cites W2017660277 @default.
• W4221036987 cites W2018792227 @default.
• W4221036987 cites W2019300527 @default.
• W4221036987 cites W2020000579 @default.
• W4221036987 cites W2032133214 @default.
• W4221036987 cites W2032240220 @default.
• W4221036987 cites W2035890213 @default.
• W4221036987 cites W2038681355 @default.
• W4221036987 cites W2039405296 @default.
• W4221036987 cites W2043000586 @default.
• W4221036987 cites W2048149415 @default.
• W4221036987 cites W2060139207 @default.
• W4221036987 cites W2062445990 @default.
• W4221036987 cites W2067346519 @default.
• W4221036987 cites W2082953267 @default.
• W4221036987 cites W2090055848 @default.
• W4221036987 cites W2100906002 @default.
• W4221036987 cites W2104795285 @default.
• W4221036987 cites W2105129455 @default.
• W4221036987 cites W2110067418 @default.
• W4221036987 cites W2122085123 @default.
• W4221036987 cites W2128364757 @default.
• W4221036987 cites W2133390842 @default.
• W4221036987 cites W2133608824 @default.
• W4221036987 cites W2137080005 @default.
• W4221036987 cites W2152727843 @default.
• W4221036987 cites W2160219101 @default.
• W4221036987 cites W2322912881 @default.
• W4221036987 cites W2516561743 @default.
• W4221036987 cites W2595176684 @default.
• W4221036987 cites W2600452401 @default.
• W4221036987 cites W2604132220 @default.
• W4221036987 cites W2606549748 @default.
• W4221036987 cites W2766021430 @default.
• W4221036987 cites W2786305788 @default.
• W4221036987 cites W2792548008 @default.
• W4221036987 cites W2808883353 @default.
• W4221036987 cites W2888217317 @default.
• W4221036987 cites W2901519529 @default.
• W4221036987 cites W2904404980 @default.
• W4221036987 cites W3157419554 @default.
• W4221036987 cites W4206481149 @default.
• W4221036987 cites W4226327181 @default.
• W4221036987 cites W4232284669 @default.
• W4221036987 cites W4249198391 @default.
• W4221036987 cites W95961711 @default.
• W4221036987 doi "https://doi.org/10.1007/s12325-022-02097-2" @default.
• W4221036987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35267155" @default.
• W4221036987 hasPublicationYear "2022" @default.
• W4221036987 type Work @default.
• W4221036987 citedByCount "3" @default.
• W4221036987 countsByYear W42210369872023 @default.
• W4221036987 crossrefType "journal-article" @default.
• W4221036987 hasAuthorship W4221036987A5018228116 @default.
• W4221036987 hasAuthorship W4221036987A5028592744 @default.
• W4221036987 hasAuthorship W4221036987A5039274182 @default.
• W4221036987 hasAuthorship W4221036987A5049671447 @default.
• W4221036987 hasAuthorship W4221036987A5054677591 @default.
• W4221036987 hasAuthorship W4221036987A5080057970 @default.
• W4221036987 hasAuthorship W4221036987A5081208955 @default.
• W4221036987 hasBestOaLocation W42210369871 @default.
• W4221036987 hasConcept C126322002 @default.
• W4221036987 hasConcept C197934379 @default.
• W4221036987 hasConcept C2776134090 @default.
• W4221036987 hasConcept C2778375690 @default.
• W4221036987 hasConcept C2779134260 @default.
• W4221036987 hasConcept C2779734285 @default.
• W4221036987 hasConcept C2779989193 @default.
• W4221036987 hasConcept C2780304432 @default.
• W4221036987 hasConcept C2781249495 @default.
• W4221036987 hasConcept C513476851 @default.
• W4221036987 hasConcept C71924100 @default.
• W4221036987 hasConcept C98274493 @default.
• W4221036987 hasConceptScore W4221036987C126322002 @default.
• W4221036987 hasConceptScore W4221036987C197934379 @default.
• W4221036987 hasConceptScore W4221036987C2776134090 @default.
• W4221036987 hasConceptScore W4221036987C2778375690 @default.

• next